<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250808</url>
  </required_header>
  <id_info>
    <org_study_id>2008ZX09312-026</org_study_id>
    <nct_id>NCT01250808</nct_id>
  </id_info>
  <brief_title>Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      Multiple Myeloma (MM) is the second diagnosed malignancy of hematological malignancies. The&#xD;
      previous study pointed out that the dosage and course of Bortezomib including the dose of&#xD;
      concomitant drugs used to treatment MM patients did not get the preferred treatment program,&#xD;
      so we are going to determine the optimal doses and course of Bortezomib through the&#xD;
      prospective, multicenter clinical trial and evaluate the efficiency and safety of different&#xD;
      program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib/Dexamethasone/Melphalan</intervention_name>
    <description>Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.&#xD;
Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.&#xD;
Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.&#xD;
Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.&#xD;
ASCT therapy:&#xD;
Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obtain informed consent form (ICF) signed by patients or its relative.&#xD;
&#xD;
          2. Patients newly diagnosed multiple myeloma (MM). (Not include patients with multiple&#xD;
             solitary extramedullary plasmacytoma and those atⅠstage of Durie-Salmon staging&#xD;
             system)&#xD;
&#xD;
          3. Measurable serum protein:&#xD;
&#xD;
             IgG type of MM: serum M-protein≥ 1.0g/dl or urine M-protein≥ 200mg/24h. IgA type of&#xD;
             MM: serum M-protein≥0.5g/dl or urine M-protein≥200mg/24h. IgM type of MM: (IgM&#xD;
             M-protein and osteolytic lesion showed in X-ray):serum protein≥ 1.0g/dl or urine&#xD;
             M-protein≥ 200mg/24h. IgD type of MM: serum M-protein≥0.05g/dl or urine&#xD;
             M-protein≥200mg/24h. Light chain type of MM: serum M-protein≥ 1.0g/dl or urine&#xD;
             M-protein≥ 200mg/24h.&#xD;
&#xD;
          4. Physical score 0~2 grade(WHO standard), and able to comply with the visit time and&#xD;
             protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with relapsed multiple myeloma.&#xD;
&#xD;
          2. Any serious diseases which may lead patients suffer from unaccepted risk.&#xD;
&#xD;
          3. Female patients who is pregnant or breast-feeding.&#xD;
&#xD;
          4. Histories of other malignant tumors other than MM, except those patients whose disease&#xD;
             have been cured for at least 3 years. Exception: basal-cell carcinoma, squamous cell&#xD;
             carcinoma, carcinoma in situ of uterine cervix, breast carcinoma in situ,occasionally&#xD;
             prostatic cancer histological discovery(at stage T1a or T1B defined as TNM&#xD;
             classification).&#xD;
&#xD;
          5. Not be able to understand or comply with the investigate protocol.&#xD;
&#xD;
          6. Patients with grade 2 or higher peripheral neuropathy before treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>xiaojun Huang</last_name>
    <phone>+86-13701389625</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Hematology,Peking University</name>
      <address>
        <city>Peking</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>jin Lu</last_name>
      <email>lujinlj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 30, 2010</study_first_submitted>
  <study_first_submitted_qc>November 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>November 30, 2010</last_update_submitted>
  <last_update_submitted_qc>November 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Huang Xiaojun</name_title>
    <organization>Institute of Hematology, Peking University.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

